APIs

Slide For More

Sl.

Product Name

Structure

Molecule details

Cas. No.

Remarks/Uses

Specification

Status

1

Sitagliptin Phosphate Monohydrate

M.F.:C16H20F6N5O6P
Mol. Wt.: 523.3

654671-77-9

It is a medication to lower blood sugar levels in adults with type 2 diabetes

EP/BP/IP/USP

Commercial

2

Dapagliflozin Propanediol

M.F.: C21H25ClO6.C3H8O2.H2O

Mol. Wt.: 502.99

960404-48-2


Uses for Type 2 Diabetes Mellitus, Heart Failure, Chronic Kidney Diseases (CKD)

Remarks: Effective in lowering HbA1c levels, improving heart and kidney outcomes

USP

Commercial

3

Vildagliptin

M.F.:C17H25N3O2
Mol. Wt.: 303.4

274901-16-5

It is used for the treatment of type II diabetes mellitus in adults.

IP

Commercial

4

Tafamidis Meglumine

M.F.: C21H25Cl2NO9

Mol. Wt.: 506.33g/mol

951395-08-7

Uses: To treat hereditary ATTR amyloidosis with polyneuropathy, and Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Remarks: Tafamidis Meglumine is the clinically used salt form of Tafamidis, developed for treating transthyretin mediated amyloidosis (ATTR). It's controlled synthesis and high purity are essential to ensure effective TTR stabilization and consistent therapeutic performance.

In-House

Commercial

5

Sacubitril-Valsartan Complex

M.F.: C96H120N12Na6O21

Mol. Wt.: 1916.02

936623-90-4

To treat chronic heart failure in adults.

In-House

Commercial

6

Sacubitril Sodium

M.F.: C24H28NNaO5

Mol. Wt.: 433.5

149690-05-1

Uses for Heart Failure (with reduced ejection fraction), Potential use in Preserved Ejection Fraction Remarks: Contraindicated with ACE inhibitors-risk of angioedeme increase

In-House

Under Scale-Up

7

 Midodrine

M.F.: C12H18N2O4 M.Wt.: 254.29

42794-76-3

Uses: Treats symptomatic orthostatic hypotension, and Dialysis-induced Hypotension

Remarks: Effective for symptomatic orthostatic hypotension and also often used in neurological conditions with autonomic failure

In-House/USP

Under Development

8

Midodrine Hydrochloride

M.F.: C12H18N2O4.HCl M.Wt.: 290.75

3092-17-9

Uses: Symptomatic Orthostatic Hypotension, Dialysis-induced hypotension and in spinal cord injury Remarks: Improves standing blood pressure, reduces dizziness, fatigue and syncope

In-House/USP

Under Development

Our APIs comply with stringent global regulatory standards, including rigorous testing for nitrosamines and elemental impurities. The manufacturing process is thoroughly validated to ensure these contaminants remain well below acceptable limits (aligned with ICH Q3D, USP <232>/<233>, EMA, and FDA guidelines). Every batch undergoes testing to guarantee safety and compliance.

Disclaimer

Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of R&D development or regulatory submissions, wherever such regulatory exemptions exist.
Scroll to Top
Ready to catalyse your next breakthrough in the pharmaceutical industry? We’d be happy to help you.

Got any queries?